NEWS CENTER

EuroPCR2023 | RainMed and SINOMED Made Their First Joint Appearance at the World Cardiovascular Conference, Bringing a New Collaborative Concept for Optimized Diagnosis and Treatment of Coronary Artery PCI

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2023-05-24 15:23
  • Views:

(Summary description)From May 16 to 19, 2023, RainMed Medical, an innovative medical device listed company from China, joined forces with its strategic partner SINOMED, a leading enterprise in the field of cardiovascular disease treatment, to showcase their original "Redefine PCI" collaborative concept at EuroPCR2023, a global academic conference for interventional cardiovascular medicine. The concept aims to provide tailored solutions for PCI procedures to optimize daily practice and bring optimized diagnostic and therapeutic solutions for coronary artery PCI.

EuroPCR2023 | RainMed and SINOMED Made Their First Joint Appearance at the World Cardiovascular Conference, Bringing a New Collaborative Concept for Optimized Diagnosis and Treatment of Coronary Artery PCI

(Summary description)From May 16 to 19, 2023, RainMed Medical, an innovative medical device listed company from China, joined forces with its strategic partner SINOMED, a leading enterprise in the field of cardiovascular disease treatment, to showcase their original "Redefine PCI" collaborative concept at EuroPCR2023, a global academic conference for interventional cardiovascular medicine. The concept aims to provide tailored solutions for PCI procedures to optimize daily practice and bring optimized diagnostic and therapeutic solutions for coronary artery PCI.

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2023-05-24 15:23
  • Views:
Information

From May 16 to 19, 2023, RainMed Medical, an innovative medical device listed company from China, joined forces with its strategic partner SINOMED, a leading enterprise in the field of cardiovascular disease treatment, to showcase their original "Redefine PCI" collaborative concept at EuroPCR2023, a global academic conference for interventional cardiovascular medicine. The concept aims to provide tailored solutions for PCI procedures to optimize daily practice and bring optimized diagnostic and therapeutic solutions for coronary artery PCI.

 

 

As one of the world's largest academic conferences in the field of interventional cardiovascular with a history of more than 30 years, this year's EuroPCR has attracted 100+ renowned medical device companies from all over the world to exhibit. According to official statistics, during the 3-day exhibition, 11,500+ of the world's top cardiovascular experts, scholars, and entrepreneurs participated in the exhibition to communicate and cooperate with their counterpart, promoting the development and innovation of the industry.

 

Last year, RainMed showcased its independently developed angiography-derived caFFR and caIMR systems for optimized diagnosis of coronary artery function. This year, RainMed teamed up with their strategic partner, SINOMED, a leading enterprise in the field of cardiovascular disease treatment and the first Chinese drug-eluting stent company approved to conduct large-scale confirmatory clinical trials before listing in the United States and Japan, to bring a new PCI solution through the collaboration of their coronary artery functional diagnosis products and heart stents. This partnership will bring new momentum into the development of both companies by leveraging the respective technologies. Furthermore, RainMed medical will be introducing its flagship technology caFFR and caIMR into the centers of PIONEERIV all-comers clinical trial as a new angio-FFR supplier in combination with the use of HT Supreme DES. This exciting development and collaboration aim to provide a tailored solution to optimize daily practice and further reduce the risk of re-intervention, and providing more precise treatments to patients.

 

"Redefine PCI", the collaboration between coronary artery functional diagnosis products and heart stents, has attracted attention and interest of authoritative distributors, hospitals, and enterprises from France, Germany, Canada, Australia, South Korea and other countries. After learning about the innovative collaborative diagnostic concept, they have given high praise and expectations for this partnership. "The collaboration in the PIONEERIV trial, with the help of international resources and cooperation network, is believed to provide important guarantee for you two enterprises' future market access and commercialization." "The non-invasive concept conveyed by caFFR and caIMR is truly exciting, as it can enable faster preoperative diagnosis, intraoperative guidance, and postoperative evaluation, which may become a better choice for doctors."

 

RainMed's first joint appearance with SINOMED at EuroPCR2023 is a proactive attempt in the field of cardiovascular product integration, which marks a new starting point for their "one-stop solution for non-invasive coronary artery intervention." The positive comments from exhibitors from all over the world have boosted our confidence. In the future, RainMed will continue to uphold the concept of "Targeted Medical Services for People's Health”, integrating caFFR and caIMR into its FlashBot vascular surgery robots to empower precision medicine and contribute to the global cardiovascular industry.

CONTACT US

0512-62622215

Address: Building 31, Northeast District, Nano City, No. 99 Jinji Lake Avenue, Suzhou industrial park

这是描述信息

WeChat public account

这是描述信息

Recruitment QR Code

We use cookies to improve our site and your shopping experience. By continuing to browse our site you accept our cookie policy. Find out more
close

Page Copyright© 2021- Suzhou Rainmed Medical Technology Co., Ltd.  苏公网安备32059002003601号  (苏)-非经营性-2021-0149